收费全文 | 498篇 |
免费 | 33篇 |
国内免费 | 8篇 |
耳鼻咽喉 | 3篇 |
儿科学 | 11篇 |
妇产科学 | 15篇 |
基础医学 | 82篇 |
口腔科学 | 27篇 |
临床医学 | 48篇 |
内科学 | 99篇 |
皮肤病学 | 20篇 |
神经病学 | 38篇 |
特种医学 | 8篇 |
外科学 | 46篇 |
综合类 | 6篇 |
一般理论 | 1篇 |
预防医学 | 50篇 |
眼科学 | 18篇 |
药学 | 37篇 |
中国医学 | 5篇 |
肿瘤学 | 25篇 |
2024年 | 1篇 |
2023年 | 24篇 |
2022年 | 43篇 |
2021年 | 39篇 |
2020年 | 29篇 |
2019年 | 49篇 |
2018年 | 43篇 |
2017年 | 26篇 |
2016年 | 17篇 |
2015年 | 29篇 |
2014年 | 25篇 |
2013年 | 31篇 |
2012年 | 46篇 |
2011年 | 45篇 |
2010年 | 20篇 |
2009年 | 12篇 |
2008年 | 13篇 |
2007年 | 9篇 |
2006年 | 9篇 |
2005年 | 5篇 |
2004年 | 10篇 |
2003年 | 5篇 |
2002年 | 7篇 |
1996年 | 2篇 |
Subject and aims
Endothelial derived nitric oxide (eNOS) is involved in several functions playing important role in development of type 2 diabetes and insulin resistance. The aim of this study was to examine the association between eNOS intron 4 VNTR polymorphism and type 2 diabetes in an Iranian population.Methods
A total of 220 patients with type 2 diabetes and 96 healthy control subjects were recruited from the same area. Genotyping was performed using PCR.Results
A significant difference was found in genotype frequencies of eNOS polymorphism between patients and controls (aa + ab vs. bb p = 0.02, OR 2.0 95% CI; 1.05-3.96). Also allele a frequency was significantly increased in patients with diabetes compared with controls (p = 0.007, OR 2.1 95% CI; 1.19-4.08). We found that in patients with diabetic neuropathy the frequency of ‘a’ allele was significantly increased compared to the controls p = 0.03, OR = 1.8 95% CI (1.00-3.7). Both genotype and allele frequencies were significantly different between patients who were complication free compared to the controls [aa + ab vs. bb p = 0.007, OR = 2.6 95% CI (1.2-5.8) and p = 0.001, OR = 2.8 95% CI (1.4-5.9)] respectively with the a allele conferring the risk.Conclusion
The association between eNOS VNTR polymorphism and T2DM seems to be stronger in patients without diabetic complications indicating diverse effect of eNOS polymorphism on diabetes and diabetic microvascular complications. 相似文献Previous studies have reported that statin or ezetimibe therapy has an anti-inflammatory effect. However, the results of individual studies on the effect of statin therapy in combination with ezetimibe on C-reactive protein (CRP) and high-sensitivity CRP (hs-CRP) levels have not been clear. Therefore, the present systematic review and meta-analysis were conducted on randomized clinical trials (RCTs) to evaluate the effect of statin therapy in combination with ezetimibe on CRP and hs-CRP levels.
MethodsA literature search was carried out on the MEDLINE, SciVerse Scopus, and Clarivate Analytics Web of Science databases up to February 2022 to find eligible studies. The pooled effect sizes were considered for weighted mean difference (WMD) and 95% confidence intervals (CI) for CRP and hs-CRP, and it was also determined as standardized weighted mean difference (SMD) for overall CRP. For all variables, a random-effects model was used.
ResultsOf the 57 studies included in the systematic review, 53 were used for meta-analysis. Statin therapy in combination with ezetimibe significantly reduced the serum levels of hs-CRP (WMD ??0.2 mg/l; 95% CI ??0.4, ??0.1, P???0.001) and overall CRP (SMD ??0.16 mg/l; 95% CI ??0.2, ??0.07, P???0.001). Nevertheless, CRP levels were not significantly changed by combination therapy. A significant association was observed between the serum low-density lipoprotein cholesterol (LDL-C) changes and hs-CRP levels, which can justify the source of heterogeneity.
ConclusionsThe current study showed that statin therapy in combination with ezetimibe could be effective in reducing the levels of hs-CRP and overall CRP.
Graphical abstract